Prof. Y.B.W.E.M. Roos PhD

foto

Prof. PhD Y.B.W.E.M. Roos

Position
Full Professor
Main activities
Education, Patient care, Research
Specialisation
Stroke
Focus of research

The Department of Neurology performs clinical and translational research within three research themes: infection & inflammation, cerebrovascular disorders, and movement disorders. The themes are imbedded in the nine translational research programs of Amsterdam Neuroscience, the research institute of neuroscience investigators in the Amsterdam area. All staff members of the Department of Neurology are involved in research and collaborate within Neuroscience Amsterdam, with other academic and non-academic hospitals, and with international research groups.

The Cerebrovascular Research Group focuses on the acute diagnostic and treatment options in both hemorrhagic and ischemic stroke, including aneurysmal subarachnoid hemorrhage and cerebral venous sinus thrombosis. Solving burning clinical questions is the starting point of the group, but where needed fundamental research is used to understand pathophysiology and develop new treatment strategies – from bed to bench and vice versa. To do so, the group has a strong clinical research infrastructure which runs large cohort studies and (international) multicenter randomized controlled trials which focus on the surveillance, testing and implementation of both new pharmacological and medical devices treatment options in acute stroke. Translational studies are focusing on early diagnostics of stroke subtypes, penumbral salvage/neuroprotection and reperfusion injury. The group is working together with all other major cerebrovascular research groups within the MR Clean and CONTRAST collaborations and is embedded in the cerebrovascular program of Amsterdam Neuroscience Center and is part of the Amsterdam Cardiovascular Sciences group.

Amsterdam UMC Research Institutes
AMC departments
Key publications
  • van den Berg Lucie A., Dijkgraaf Marcel G. W., Berkhemer Olvert A., Fransen Puck S. S., Beumer Debbie, Lingsma Hester F., Majoie Charles B. L. M., Dippel Diederik W. J., van der Lugt Aad, van Oostenbrugge Robert J., van Zwam Wim H., Roos Yvo B. W. E. M., Yoo Albert J., Schonewille Wouter J., Vos Jan Albert, Nederkoorn Paul J., Wermer Marieke J. H., van Walderveen Marianne A. A., Staals Julie, Hofmeijer Jeannette, van Oostayen Jacques A., Lycklama à Nijeholt Geert J., Boiten Jelis, Brouwer Patrick A., Emmer Bart J., de Bruijn Sebastiaan F., van Dijk Lukas C., Kappelle L. Jaap, Lo Rob H., van Dijk Ewoud J., de Vries Joost, de Kort Paul L. M., van den Berg Jan S. P., van Hasselt Boudewijn A. A. M., Aerden Leo A. M., Dallinga René J., Visser Marieke C., Bot Joseph C. J., Vroomen Patrick C., Eshghi Omid, Schreuder Tobien H. C. M. L., Heijboer Roel J. J., Keizer Koos, Tielbeek Alexander V., den Hertog Heleen M., Gerrits Dick G., Marquering Henk A., Sprengers Marieke E. S., Beenen Ludo F. M., van den Berg René Two-Year Outcome after Endovascular Treatment for Acute Ischemic Stroke New England journal of medicine 2017;376 (14):1341-1349 [PubMed]
  • Baharoglu M. Irem, Cordonnier Charlotte, Al-Shahi Salman Rustam, de Gans Koen, Koopman Maria M., Brand Anneke, Majoie Charles B., Beenen Ludo F., Marquering Henk A., Vermeulen Marinus, Nederkoorn Paul J., de Haan Rob J., Roos Yvo B., Reitsma J. B., Kamphuisen P. W., Touzé E., Lasne D., François A., Baharoglu Irem, Zinkstok Sanne, Coutinho Jonathan, Boers Merel, Geuskens Ralph, Hart Groene, Bloodbank Sanquin, Koopman Rianne, de Graaf Reinier, Aerden Leo, Vermeer Sarah, Schreuder Tobien, Schuiling Wouter, Haag Den, Bienfait Henriette, Bakker Stef, Ziekenhuis Canisius Wilhelmina, Klijn Catharina, Bronner Irene, Ziekenhuis St Elisabeth, de Kort Paul, Raaijmakers Dianne, Visser Marieke, Ziekenhuis Catharina, Keizer Koos, Jansen Ben, Ziekenhuis Kruis, van der Willem, Rooyer Fergus, Verhey Hans, Macleod Mary Joan, Joyson Anu Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial Lancet 2016;387 (10038):2605-2613 [PubMed]
  • Berkhemer Olvert A., Fransen Puck S. S., Beumer Debbie, van den Berg Lucie A., Lingsma Hester F., Yoo Albert J., Schonewille Wouter J., Vos Jan Albert, Nederkoorn Paul J., Wermer Marieke J. H., van Walderveen Marianne A. A., Staals Julie, Hofmeijer Jeannette, van Oostayen Jacques A., Lycklama à Nijeholt Geert J., Boiten Jelis, Brouwer Patrick A., Emmer Bart J., de Bruijn Sebastiaan F., van Dijk Lukas C., Kappelle L. Jaap, Lo Rob H., van Dijk Ewoud J., de Vries Joost, de Kort Paul L. M., van Rooij Willem Jan J., van den Berg Jan S. P., van Hasselt Boudewijn A. A. M., Aerden Leo A. M., Dallinga René J., Visser Marieke C., Bot Joseph C. J., Vroomen Patrick C., Eshghi Omid, Schreuder Tobien H. C. M. L., Heijboer Roel J. J., Keizer Koos, Tielbeek Alexander V., den Hertog Heleen M., Marquering Henk A., Sprengers Marieke E. S., Beenen Ludo F. M., van den Berg René, Roos Yvo B. W. E. M., Majoie Charles B. L. M., Santos Emilie, Borst Jordi, Jansen Ivo, Lucas Marit, Barros Renan Sales A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke New England journal of medicine 2015;372 (1):11-20 [PubMed]
  • Zinkstok Sanne M., Roos Yvo B., Aerden L. A. M., van den Berg-Vos R. M., Bakker S. L. M., Bienfait H. M. E., Bienfait H. P., Boon A. E., Brans J. W. M., Bronner I. M., de Bruijn S. F. T. M., Franke C. L., Hofstee D. J., Jansen B. P. W., Jellema K., Kalkers N. F., Portegies P., Keizer K., Kerkhoff H., de Gans K., Kloos L. M. H., Kok A. J. M., de Kort P. L. M., de Kruijk J. R., van der Kruijk R. A., Kwa V. I. H., Kruyt N. D., Meijer R. J., van der Meulen W. D. M., Mulleners W. M., Nederkoorn P. J., van der Ree T. C., Rooyer F. A., Saxena R., Schuiling W. J., Verbiest H. B. C., Verhey J. C. B., Vermeer S. E., Visée H. F., Visser M. C., van der Wiel H. L., van der Worp H. B., de Haan R. J., Stam J., Vermeulen M., Peters R. J. G., Majoie C. B. L. M., Beenen L. F., Marquering H. A., van Geloven N. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial Lancet 2012;380 (9843):731-737 [PubMed]
  • Roos Yvo B. W. E. M. Tranexamic acid for traumatic brain injury BMJ (Clinical research ed.) 2011;343:d3958 [PubMed]
All Publications
Curriculum Vitae

1a Personal details
• Title(s), initial(s), first name, surname: Prof. Dr. Yvo BWEM Roos
• Current position: Professor of Acute Neurology, Board Certified Neurologist, Principle Investigator Neurology

1b Education/training
Master's (‘doctoraal’)
• University/College of Higher Education: Erasmus University Rotterdam
• Date: 18-01-1991
• Studies: Medicine
• Main subject: General medicine

Doctorate/PhD (‘promotie’)
• University/College of Higher Education: University of Amsterdam
• Date: 31-03-2000
• Supervisor (‘Promotor’): Prof.Dr. M. Vermeulen and Prof.Dr. R.J. de Haan
• Title of thesis: Fibrinolysis and antifibrinolytic treatment in aneurysmal subarachnoid hemorrhage
• Registration as a specialist (dd/mm/yy): 01-09-2002
• Medical specialty: Neurology

2. Positions and Honours

I. Positions and employment
2002-present; Board Certified Neurologist, Staff member from 2003; 2010-present: Principle Investigator Neurology AMC; 2013-present; Professor of Acute Neurology at the Academic Medical Center Amsterdam (AMC). 2013-present; Coordinator of both Bachelor and Master teaching Neurology at the University of Amsterdam, head of Neurology residency program in the Academic Medical Center, Amsterdam.

II. Other relevant experience and professional memberships
2006-present: Head of Acute Brain Care Unit AMC; 2008 -present: Delegate of the Dutch Society of Neurology at the Nederlands Neurovasculair Genootschap (NNG); 2011 -present: Executive board member of the Neurovascular Intervention Center Amsterdam (NICA); 2012-2013: Member Clinical Established Investigator committee, Dutch Heart Foundation (NHS); 2012-2014: Chairman Amsterdamsche Neurologenvereeniging; 2013-present: Examination committee member of the University of Amsterdam Medical School, The Netherlands.

III. Honours and awards
2007: Univé Palludanus Price for the best medical care improvement initiative (Brain Care Unit);

2013, 2014, 2015, 2016: Prices for Best Medical School Teacher and Best Teaching Course (Bachelor), University of Amsterdam, The Netherlands;

2017: Winner of the 'Wetenschaps- en Innovatieprijs 2017 van de Federatie Medisch Specialisten' for the Mr Clean study;

Research programmes

Prof. PhD Y.B.W.E.M. Roos (Stroke)

The main focus of the research group is on the acute treatment of stroke. The group members (lead by Dr. P.J. Nederkoorn, Dr. J. Coutinho and myself) are conducting randomised clinical trials in both ischemic and hemorrhagic stroke and in cerebral venous thrombosis. The group is actively participating in the stroke 'pearl-string' project and is both initiating and participating in several important national and international studies. Although the main focus is on acute treatment, some spin-off studies are also investigating some pathophysiological mechanisms, both to support hypotheses to be evaluated in the acute trials or to explain effects found in the acute studies.

Personally Yvo Roos was the principle investigator (PI) of the in 2012 in the Lancet published ARTIS study, investigating the addition of aspirin to iv thrombolysis in acute ischemic stroke. He was PI of the recently finished PATCH study, an International randomised clinical trial investigating the clinical efficacy of acute platelet transfusion in patients with an intracerebral haemorrhage while on antiplatelet therapy. Last year the results were published in The Lancet. Surprisingly they showed that platelet transfusion induces an increase in poor outcome by increasing hematoma growth. Additional pathophysiological studies to explain these results are currently being setup. Yvo Roos is also PI of the CLOT MR Clean trial. This extension of the Mr Clean study was funded by ZONMW and looked at both long term follow-up and cost effectiveness. The results on two year follow up are recently (April 2017) published in the NEJM.
Results of the Mr Clean Cost Effectiveness study are in a final stage and will be submitted to The Lancet shortly. Within the newly initiated clinical studies (see below) the experience gathered with the long term follow-up and cost effectiveness will be used to setup new side-line studies.

Research will continue to focus on acute stroke treatment. Yvo Roos is one of the PI’s of the CONTRAST consortium, funded (>10.000.000 euro) by CVON and industry partners. Within CONTRAST Yvo Roos is one of the two PI’s of the NoIV study, one of the main clinical studies.

Faculty
MD PhD J. Coutinho
MD PhD P.J. Nederkoorn

Postdocs
MD PhD S.M. Zinkstok
MD PhD S.M. Zuurbier

Others
G.P.A. Clerx
N.M. Fleitour
R.G. Sprengers

Current PhD Candidates
Current research funding
  • AMC
  • AMC (Vrijgesteld)
  • ITREAS B.V.
  • Nederlandse Hartstichting